TY - JOUR
T1 - 5-ASA for Ulcerative Colitis
AU - Meyers, Samuel
AU - Janowitz, Henry D.
AU - Schroeder, Kenneth W.
AU - Tremaine, William J.
AU - Ilstrup, Duane M.
AU - Morrey, Bernard F.
PY - 1988/6/16
Y1 - 1988/6/16
N2 - To the Editor: The therapeutic results reported in the paper entitled “Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis” (Dec. 24 issue)1 were very encouraging, in view of our previously reported data with olsalazine sodium.2 However, we were surprised that the patients in the placebo group were denied available standard therapy, in the form of sulfasalazine. The authors themselves stated that sulfasalazine is effective to “induce remission of mildly to moderately active disease.” In our study, the placebo group was limited to patients who were intolerant of or allergic to sulfasalazine.2 We considered entry into the.
AB - To the Editor: The therapeutic results reported in the paper entitled “Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis” (Dec. 24 issue)1 were very encouraging, in view of our previously reported data with olsalazine sodium.2 However, we were surprised that the patients in the placebo group were denied available standard therapy, in the form of sulfasalazine. The authors themselves stated that sulfasalazine is effective to “induce remission of mildly to moderately active disease.” In our study, the placebo group was limited to patients who were intolerant of or allergic to sulfasalazine.2 We considered entry into the.
UR - http://www.scopus.com/inward/record.url?scp=0023929847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023929847&partnerID=8YFLogxK
U2 - 10.1056/NEJM198806163182415
DO - 10.1056/NEJM198806163182415
M3 - Letter
C2 - 3287160
AN - SCOPUS:0023929847
VL - 318
SP - 1620
EP - 1621
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 24
ER -